Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Am J Med Genet A ; 191(12): 2837-2842, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37554039

RESUMEN

Left main coronary artery ostial atresia (LMCAOA) is an extremely rare condition. Here, we report the case of a 14-year-old boy with Noonan syndrome-like disorder in whom LMCAOA was detected following cardiopulmonary arrest. The patient had been diagnosed with Noonan syndrome-like disorder with a pathogenic splice site variant of CBL c.1228-2 A > G. He suddenly collapsed when he was running. After administering two electric shocks using an automated external defibrillator, the patient's heartbeat resumed. Cardiac catheterization confirmed the diagnosis of LMCAOA. Left main coronary artery angioplasty was performed. The patient was discharged without neurological sequelae. Brain magnetic resonance imaging revealed asymptomatic Moyamoya disease. In addition, RNF213 c.14429 G > A p.R4810K was identified. There are no reports on congenital coronary malformations of compound variations of RNF213 and CBL. In contrast, the RNF213 p.R4810K polymorphism has been established as a risk factor for angina pectoris and myocardial infarction in adults, and several congenital coronary malformations due to genetic abnormalities within the RAS/MAPK signaling pathway have been reported. This report aims to highlight the risk of sudden death in patients with RASopathy and RNF213 p.R4810K polymorphism and emphasize the significance of actively searching for coronary artery morphological abnormalities in these patients.


Asunto(s)
Anomalías Múltiples , Paro Cardíaco , Enfermedad de Moyamoya , Síndrome de Noonan , Adulto , Masculino , Humanos , Niño , Adolescente , Vasos Coronarios/diagnóstico por imagen , Vasos Coronarios/metabolismo , Síndrome de Noonan/complicaciones , Síndrome de Noonan/diagnóstico , Síndrome de Noonan/genética , Predisposición Genética a la Enfermedad , Adenosina Trifosfatasas/genética , Ubiquitina-Proteína Ligasas/genética , Enfermedad de Moyamoya/genética , Paro Cardíaco/genética
2.
Mol Genet Genomic Med ; 11(7): e2190, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-37186429

RESUMEN

Barth syndrome (BTHS) is an X-linked disorder characterized by cardiomyopathy, skeletal myopathy, and 3-methylglutaconic aciduria. The causative pathogenic variants for BTHS are in TAZ, which encodes a putative acyltransferase named tafazzin and is involved in the remodeling of cardiolipin in the inner mitochondrial membranes. Pathogenic variants in TAZ result in mitochondrial structural and functional abnormalities. We report a case of infantile BTHS with severe heart failure, left ventricular noncompaction, and lactic acidosis, having a missense c.640C>T (p.His214Tyr) variant in TAZ, which is considered a pathogenic variant based on the previously reported amino acid substitution at the same site (c.641A>G, p.His214Arg). However, in this previously reported case, heart function was compensated and not entirely similar to the present case. Silico prediction analysis suggested that c.640C>T could alter the TAZ messenger RNA (mRNA) splicing process. TAZ mRNAs in isolated peripheral mononuclear cells from the patient and in vitro splicing analysis using minigenes of TAZ found an 8 bp deletion at the 3' end of exon 8, which resulted in the formation of a termination codon in the coding region of exon 9 (H214Nfs*3). These findings suggest that splicing abnormalities should always be considered in BTHS.


Asunto(s)
Síndrome de Barth , Cardiomiopatías , Cardiopatías Congénitas , Insuficiencia Cardíaca , Humanos , Síndrome de Barth/genética , Síndrome de Barth/patología , Cardiomiopatías/genética , Cardiopatías Congénitas/genética , Insuficiencia Cardíaca/genética , Factores de Transcripción/genética
3.
Front Pediatr ; 10: 909595, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35783314

RESUMEN

Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, which negatively impacts the patient's quality of life and frequently results in complications, such as catheter-related bloodstream infection. We weaned an adolescent female patient off epoprostenol by gradually introducing oral selexipag over a sustained period, following many years of continuous intravenous epoprostenol use alone. Oral selexipag might have an efficacy comparable to epoprostenol in young patients with PAH.

4.
CJC Pediatr Congenit Heart Dis ; 1(5): 229-231, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37969429

RESUMEN

We report the case of an adult who had a cardiac arrest in the setting of pulmonary hypertension and a previously repaired intermediate atrioventricular septal defect, with left main coronary trunk stenosis due to dilatation of the main pulmonary artery. In patients with pulmonary hypertension exhibiting anginal symptoms, it is advisable to perform chest contrast computed tomography to confirm the pulmonary artery diameter and the presence of coronary artery compression. In addition, our case highlights the importance of early collaboration among specialists during the transition from adolescence to adulthood.


Nous décrivons le cas d'un adulte ayant subi un arrêt cardiaque alors qu'il présentait une hypertension pulmonaire et qu'il avait déjà subi la réparation d'une communication septale auriculoventriculaire intermédiaire, avec sténose de l'artère coronaire gauche principale causée par la dilatation de l'artère pulmonaire principale. Chez les patients atteints d'hypertension pulmonaire qui présentent des symptômes angineux, il est recommandé d'effectuer une tomodensitométrie thoracique avec produit de contraste pour confirmer le diamètre de l'artère pulmonaire et la présence d'une compression de l'artère coronaire. Notre cas souligne également l'importance d'établir sans tarder une collaboration entre spécialistes lors de la transition entre l'adolescence et l'âge adulte.

5.
BMC Cardiovasc Disord ; 21(1): 389, 2021 08 11.
Artículo en Inglés | MEDLINE | ID: mdl-34380423

RESUMEN

BACKGROUND: We report a rare case of left ventricular inflow obstruction from a branch of the left circumflex coronary artery to the right atrium caused by a coronary arteriovenous fistula (CAVF) in a young Japanese male child. CASE PRESENTATION: The patient was diagnosed with CAVF following a heart murmur shortly after birth. The left-to-right shunt caused right ventricular volume overload and pulmonary congestion. An emergency surgical intervention was performed for the CAVF on day 6 after birth. However, by 5 years of age, his left ventricular inflow obstruction worsened. We found an abnormal blood vessel originating from the proximal part of a branch of the left circumflex coronary artery, circling the outside of the mitral valve annulus along the medial side of the coronary sinus. As the child gets older, the blood inflow into the left ventricle might get restricted further, resulting in left-sided heart failure. CONCLUSION: Our findings suggest that even after CAVF closure surgery, it is essential to monitor for complications caused by progressive dilatation of a persistent CAVF.


Asunto(s)
Fístula Arteriovenosa/complicaciones , Anomalías de los Vasos Coronarios/complicaciones , Ventrículos Cardíacos , Hiperemia/etiología , Factores de Edad , Fístula Arteriovenosa/cirugía , Preescolar , Seno Coronario , Anomalías de los Vasos Coronarios/cirugía , Dilatación Patológica/complicaciones , Humanos , Hipocinesia/diagnóstico por imagen , Recién Nacido , Masculino , Válvula Mitral , Venas Pulmonares , Disfunción Ventricular Izquierda/diagnóstico por imagen
6.
Int J Mol Sci ; 23(1)2021 Dec 22.
Artículo en Inglés | MEDLINE | ID: mdl-35008537

RESUMEN

The development of drug delivery systems for use in the treatment of cardiovascular diseases is an area of great interest. We report herein on an evaluation of the therapeutic potential of a myocardial mitochondria-targeting liposome, a multifunctional envelope-type nano device for targeting pancreatic ß cells (ß-MEND) that was previously developed in our laboratory. Resveratrol (RES), a natural polyphenol compound that has a cardioprotective effect, was encapsulated in the ß-MEND (ß-MEND (RES)), and its efficacy was evaluated using rat myocardioblasts (H9c2 cells). The ß-MEND (RES) was readily taken up by H9c2 cells, as verified by fluorescence-activated cell sorter data, and was observed to be colocalized with intracellular mitochondria by confocal laser scanning microscopy. Myocardial mitochondrial function was evaluated by a Seahorse XF Analyzer and the results showed that the ß-MEND (RES) significantly activated cellular maximal respiratory capacity. In addition, the ß-MEND (RES) showed no cellular toxicity for H9c2 cells as evidenced by Premix WST-1 assays. This is the first report of the use of a myocardial mitochondria-targeting liposome encapsulating RES for activating mitochondrial function, which was clearly confirmed based on analyses using a Seahorse XF Analyzer.


Asunto(s)
Respiración de la Célula/efectos de los fármacos , Liposomas/química , Mitocondrias Cardíacas/efectos de los fármacos , Miocitos Cardíacos/efectos de los fármacos , Resveratrol/farmacología , Animales , Línea Celular , Células Secretoras de Insulina/efectos de los fármacos , Nanopartículas/química , Polifenoles/química , Ratas , Resveratrol/química
7.
Int J Mol Sci ; 21(17)2020 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-32887310

RESUMEN

Mitochondrial transplantation therapy is an innovative strategy for the treatment of mitochondrial dysfunction. The approach has been reported to be useful in the treatment of cardiac ischemic reperfusion injuries in human clinical trials and has also been shown to be useful in animal studies as a method for treating mitochondrial dysfunction in various tissues, including the heart, liver, lungs, and brain. On the other hand, there is no methodology for using preserved mitochondria. Research into the pharmaceutical formulation of mitochondria to promote mitochondrial transplantation therapy as the next step in treating many patients is urgently needed. In this review, we overview previous studies on the therapeutic effects of mitochondrial transplantation. We also discuss studies related to immune responses that occur during mitochondrial transplantation and methods for preserving mitochondria, which are key to their stability as medicines. Finally, we describe research related to mitochondrial targeting drug delivery systems (DDS) and discuss future perspectives of mitochondrial transplantation.


Asunto(s)
Sistemas de Liberación de Medicamentos , Liposomas/química , Mitocondrias/trasplante , Enfermedades Mitocondriales/terapia , Animales , Humanos , Enfermedades Mitocondriales/patología
8.
J Clin Pathol ; 2020 Aug 17.
Artículo en Inglés | MEDLINE | ID: mdl-32817174

RESUMEN

AIMS: Mitochondrial cardiomyopathy (MCM) is difficult to make a definite diagnosis because of various cardiovascular phenotypes and no diagnostic criteria in the pathology examination. We aim to add myocardial pathology to the diagnostic criteria for mitochondrial respiratory chain disorders. METHODS: Quantitative analysis of mitochondria using electron microscopy and immunohistopathological analysis with respiratory chain enzyme antibodies were performed in 11 patients with hypertrophic or restrictive cardiomyopathy who underwent endomyocardial biopsy for possible MCM . Respiratory chain enzymatic assay in biopsied myocardium and genetic studies were also performed in all the subjects to define MCM. RESULTS: Four patients were diagnosed with MCM according to the recent criteria of mitochondrial respiratory chain disorders. Using electron microscopy with quantitative analysis, the volume density of mitochondria within cardiac muscle cells was significantly increased in the MCM group compared with the non-MCM group (p=0.007). Immunohistopathological results were compatible with the result of the respiratory chain enzymatic assay. CONCLUSIONS: Pathological diagnosis of MCM could be confirmed by a quantitative study of electron microscopy and immunohistopathological analysis using the mitochondrial respiratory chain enzyme subunit antibody.

9.
Heart Vessels ; 35(9): 1307-1315, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32285188

RESUMEN

Congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) is one of the major complications in patients with CHD. A timely closure of the left-to-right shunt will generally result in the normalization of the pulmonary hemodynamics, but a few patients have severe prognosis in their early childhood. We hypothesized that wide-ranging pathological mechanism in PAH could elucidate the clinical state of severe CHD-PAH. Using electronic medical records, we retrospectively analyzed six infants with severe CHD-PAH who had treatment-resistant PH. All patients were born with congenital malformation syndrome. After starting on a pulmonary vasodilator, five of the six patients developed complications including pulmonary edema and interstitial lung disease (ILD), and four patients had alveolar hemorrhage. After steroid therapy, the clinical condition improved in four patients, but two patients died. The autopsy findings in one of the deceased patients indicated the presence of recurrent alveolar hemorrhage, pulmonary venous hypertension, ILD, and PAH. Based on the clinical course of these CHD-PAH in patients and the literature, CHD-PAH can occur with pulmonary vascular obstructive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH), ILD, and/or alveolar hemorrhage. The severity of CHD-PAH may depend on a genetic disorder, respiratory infection, and upper airway stenosis. Additionally, pulmonary vasodilators may be involved in the development of PVOD/PCH and ILD. When patients with CHD-PAH show unexpected deterioration, clinicians should consider complications associated with PVOD/PCH and/or pulmonary disease. In addition, the choice of upfront combination therapy for pediatric patients with CHD-PAH should be selected carefully.


Asunto(s)
Antihipertensivos/efectos adversos , Presión Arterial/efectos de los fármacos , Cardiopatías Congénitas/complicaciones , Hipertensión Arterial Pulmonar/tratamiento farmacológico , Arteria Pulmonar/efectos de los fármacos , Vasodilatadores/efectos adversos , Femenino , Cardiopatías Congénitas/diagnóstico por imagen , Cardiopatías Congénitas/fisiopatología , Cardiopatías Congénitas/cirugía , Hemangioma Capilar/complicaciones , Hemangioma Capilar/fisiopatología , Hemorragia/etiología , Hemorragia/fisiopatología , Humanos , Lactante , Recién Nacido , Enfermedades Pulmonares Intersticiales/etiología , Enfermedades Pulmonares Intersticiales/fisiopatología , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/fisiopatología , Masculino , Hipertensión Arterial Pulmonar/diagnóstico , Hipertensión Arterial Pulmonar/etiología , Hipertensión Arterial Pulmonar/fisiopatología , Arteria Pulmonar/fisiopatología , Edema Pulmonar/etiología , Edema Pulmonar/fisiopatología , Enfermedad Veno-Oclusiva Pulmonar/etiología , Enfermedad Veno-Oclusiva Pulmonar/fisiopatología , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento
10.
Mod Rheumatol ; 28(1): 108-113, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28612674

RESUMEN

OBJECTIVES: Acute leukemia often causes osteoarthralgia. The aim of this study is characterization of leukemia-associated osteoarthralgia in comparison with juvenile idiopathic arthritis (JIA). METHODS: We retrospectively reviewed clinical records of 31 patients with acute leukemia and 13 patients with articular JIA diagnosed between January 2008 and March 2013. Clinical and laboratory findings at the initial examination were compared among the three groups; 10 leukemia with and 21 leukemia without osteoarthralgia and 13 JIA groups. RESULTS: Eleven of the 31 leukemic patients (35%) had osteoarthralgia before the diagnosis of leukemia. Peripheral leukemic cells were initially absent in 10 of the 31 leukemia patients including three with osteoarthralgia. Platelet counts over 300 × 109/L were common in JIA, but not in osteoarthralgia group. Mean serum lactate dehydrogenase levels were higher in both of the leukemia groups than JIA group but often within normal or near-normal levels in the leukemia groups. Magnetic resonance imaging was examined in three leukemic patients and demonstrated osteomyelitis-like bone marrow edema in two and periarticular infiltration similar to synovitis in one patient. Three leukemic patients with osteoarthralgia showed partial and transient responses to antibiotic therapy. CONCLUSIONS: Leukemia-associated osteoarthralgia is often indistinguishable from rheumatic diseases by imaging and laboratory findings and should be confirmed by bone marrow examination.


Asunto(s)
Artralgia/diagnóstico por imagen , Artritis Juvenil/diagnóstico por imagen , Médula Ósea/diagnóstico por imagen , Edema/diagnóstico por imagen , Leucemia/diagnóstico por imagen , Dolor/diagnóstico por imagen , Artralgia/etiología , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Humanos , Leucemia/complicaciones , Imagen por Resonancia Magnética/métodos , Masculino , Dolor/etiología , Estudios Retrospectivos
11.
J Pediatr Hematol Oncol ; 37(4): e238-41, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25171454

RESUMEN

We describe a boy with Schinzel-Giedion syndrome who developed refractory sacrococcygeal germ cell tumor with elements of embryonal carcinoma and immature teratoma. He developed local recurrence soon after tumor resection. The tumor was highly resistant to platinum-based combination chemotherapy, local irradiation, and salvage chemotherapy. Frequent infections resulted in a delay in treatment, although apparent fragility had not been observed clinically. He died from tumor progression at 32 months of age. Intensification of chemotherapy does not seem to be feasible for tumors in patients with Schinzel-Giedion syndrome.


Asunto(s)
Anomalías Craneofaciales/complicaciones , Deformidades Congénitas de la Mano/complicaciones , Discapacidad Intelectual/complicaciones , Uñas Malformadas/complicaciones , Neoplasias de Células Germinales y Embrionarias/terapia , Anomalías Múltiples , Proteínas Portadoras/genética , Preescolar , Humanos , Masculino , Mutación , Neoplasias de Células Germinales y Embrionarias/etiología , Neoplasias de Células Germinales y Embrionarias/genética , Proteínas Nucleares/genética , Región Sacrococcígea
12.
Eur J Neurosci ; 25(3): 659-72, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17298601

RESUMEN

Phospholipase Cbeta3 (PLCbeta3) and PLCbeta4 are the two major isoforms in cerebellar Purkinje cells (PCs), displaying reciprocal expression across the cerebellum. Here, we examined subcellular distribution of PLCbeta3 in the mouse cerebellum by producing specific antibody. PLCbeta3 was detected as a particulate pattern of immunostaining in various PC elements. Like PLCbeta4, PLCbeta3 was richly distributed in somatodendritic compartments, where it was colocalized with molecules constituting the metabotropic glutamate receptor (mGluR1) signalling pathway, i.e. mGluR1alpha, G alpha q/G alpha 11 subunits of G q protein, inositol 1,4,5-trisphosphate receptor IP3R1, Homer1, protein kinase C PKCgamma, and diacylglycerol lipase DAGLalpha. Unlike PLCbeta4, PLCbeta3 was also distributed at low to moderate levels in PC axons, which were intense for IP3R1 and PKCgamma, low for G alpha q/G alpha 11, and negative for mGluR1alpha, Homer1, and DAGLalpha. By immunoelectron microscopy, PLCbeta3 was preferentially localized around the smooth endoplasmic reticulum in spines, dendrites, and axons of PCs, and also accumulated at the perisynapse of parallel fibre-PC synapses. Consistent with the ultrastructural localization, PLCbeta3 was biochemically enriched in the microsomal and postsynaptic density fractions. These results suggest that PLCbeta3 plays a major role in mediating mGluR1-dependent synaptic transmission, plasticity, and integration in PLCbeta3-dominant PCs, through eliciting Ca2+ release, protein phosphorylation, and endocannabinoid production at local somatodendritic compartments. Because PLCbeta3 can be activated by G betagamma subunits liberated from Gi/o and Gs proteins as well, axonal PLCbeta3 seems to modulate the conduction of action potentials through mediating local Ca2+ release and protein phosphorylation upon activation of a variety of G protein-coupled receptors other than mGluR1.


Asunto(s)
Axones/enzimología , Espinas Dendríticas/enzimología , Isoenzimas/metabolismo , Células de Purkinje/enzimología , Fosfolipasas de Tipo C/metabolismo , Animales , Anticuerpos , Especificidad de Anticuerpos , Axones/ultraestructura , Calcio/metabolismo , Compartimento Celular/fisiología , Espinas Dendríticas/ultraestructura , Retículo Endoplásmico/enzimología , Retículo Endoplásmico/ultraestructura , Proteínas de Unión al GTP/metabolismo , Isoenzimas/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microscopía Inmunoelectrónica , Fosfolipasa C beta , Células de Purkinje/ultraestructura , Receptores de Glutamato Metabotrópico/metabolismo , Sinapsis/enzimología , Sinapsis/ultraestructura , Fosfolipasas de Tipo C/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA